Oncology Biosimilars

pfizer oncology biosimilars

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SPC for how to report adverse reactions.

References:
  1. Data on file. Pfizer oncology strategy and pipeline. Pfizer Inc.
  2. TRAZIMERA® Summary of Product Characteristics.
  3. ZIRABEV® Summary of Product Characteristics.
  4. RUXIENCE® Summary of Product Characteristics.
  5. NIVESTIM® Summary of Product Characteristics. 

PP-BIO-IRL-0098 Preparation Date: August 2021